Humana Inc (NYSE:HUM) – Stock analysts at Cantor Fitzgerald boosted their FY2019 earnings per share (EPS) estimates for shares of Humana in a report released on Thursday, November 7th. Cantor Fitzgerald analyst S. Halper now expects that the insurance provider will post earnings per share of $17.80 for the year, up from their prior forecast of $17.60. Cantor Fitzgerald currently has a “Overweight” rating and a $345.00 target price on the stock. Cantor Fitzgerald also issued estimates for Humana’s FY2020 earnings at $18.70 EPS.
Other equities research analysts also recently issued reports about the company. Citigroup boosted their target price on Humana from $340.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday. Mizuho started coverage on Humana in a report on Thursday, October 17th. They issued a “buy” rating and a $316.00 target price on the stock. UBS Group boosted their target price on Humana from $266.00 to $317.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st. Canaccord Genuity reissued a “buy” rating on shares of Humana in a report on Monday, October 21st. Finally, JPMorgan Chase & Co. boosted their target price on Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the stock. Humana has an average rating of “Buy” and an average target price of $335.45.
Humana stock traded up $1.08 during mid-day trading on Friday, hitting $316.22. The company had a trading volume of 33,296 shares, compared to its average volume of 901,090. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.37. The stock’s 50 day moving average price is $276.72 and its two-hundred day moving average price is $270.55. Humana has a 12 month low of $225.65 and a 12 month high of $353.05. The company has a market capitalization of $39.82 billion, a PE ratio of 21.74, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85.
Humana (NYSE:HUM) last released its earnings results on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.58 by $0.45. Humana had a return on equity of 22.47% and a net margin of 4.13%. The business had revenue of $16.24 billion for the quarter, compared to the consensus estimate of $16.15 billion. During the same period in the previous year, the company posted $4.58 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year.
A number of institutional investors have recently made changes to their positions in the stock. MUFG Americas Holdings Corp lifted its stake in shares of Humana by 21.3% in the 3rd quarter. MUFG Americas Holdings Corp now owns 519 shares of the insurance provider’s stock valued at $133,000 after purchasing an additional 91 shares during the last quarter. First Allied Advisory Services Inc. lifted its stake in shares of Humana by 3.9% in the 3rd quarter. First Allied Advisory Services Inc. now owns 6,061 shares of the insurance provider’s stock valued at $1,581,000 after purchasing an additional 225 shares during the last quarter. Rational Advisors LLC lifted its stake in shares of Humana by 947.6% in the 3rd quarter. Rational Advisors LLC now owns 220 shares of the insurance provider’s stock valued at $56,000 after purchasing an additional 199 shares during the last quarter. Corient Capital Partners LLC lifted its stake in shares of Humana by 29.7% in the 3rd quarter. Corient Capital Partners LLC now owns 1,525 shares of the insurance provider’s stock valued at $390,000 after purchasing an additional 349 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Humana by 108.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 282 shares of the insurance provider’s stock worth $72,000 after buying an additional 147 shares during the period. 92.93% of the stock is owned by institutional investors.
In related news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the transaction, the insider now directly owns 12,994 shares of the company’s stock, valued at $3,764,361.80. The sale was disclosed in a filing with the SEC, which is available through this link. 0.54% of the stock is currently owned by corporate insiders.
The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.70%. The ex-dividend date is Monday, December 30th. Humana’s payout ratio is presently 15.12%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: What is a Roth IRA?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.